Cargando…

Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice

Background: We aimed to explore the relative dose intensity (RDI) and post-regorafenib treatments in regorafenib therapy. Methods: The medical records of 38 patients treated with regorafenib between July 2017 and June 2019 at our institution were collected. The RDI of regorafenib for the first month...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Wan, Tsuchiya, Kaoru, Kurosaki, Masayuki, Yasui, Yutaka, Inada, Kento, Kirino, Sakura, Yamashita, Koji, Sekiguchi, Shuhei, Hayakawa, Yuka, Osawa, Leona, Okada, Mao, Higuchi, Mayu, Takaura, Kenta, Maeyashiki, Chiaki, Kaneko, Shun, Tamaki, Nobuharu, Nakanishi, Hiroyuki, Itakura, Jun, Takahashi, Yuka, Asahina, Yasuhiro, Enomoto, Nobuyuki, Izumi, Namiki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826625/ https://www.ncbi.nlm.nih.gov/pubmed/31601010 http://dx.doi.org/10.3390/cancers11101517

Ejemplares similares

Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy
por: Sekiguchi, Shuhei, et al.
Publicado: (2022)

The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy
por: Takaura, Kenta, et al.
Publicado: (2022)

Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma
por: Kirino, Sakura, et al.
Publicado: (2020)

Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis
por: Inada, Kento, et al.
Publicado: (2021)

Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup
por: Tamaki, Nobuharu, et al.
Publicado: (2020)

Early radiological response evaluation with response evaluation criteria in solid tumors 1.1 stratifies survival in hepatocellular carcinoma patients treated with lenvatinib
por: Kaneko, Shun, et al.
Publicado: (2020)

Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir
por: Tamaki, Nobuharu, et al.
Publicado: (2019)

Impaired brain function improved by l-carnitine in patients with cirrhosis: evaluation using near-infrared spectroscopy
por: Nakanishi, Hiroyuki, et al.
Publicado: (2020)

Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma
por: Takada, Hitomi, et al.
Publicado: (2019)

Detecting advanced liver fibrosis using ultrasound shear wave velocity measurement in the general population
por: Kirino, Sakura, et al.
Publicado: (2023)

Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma
por: Kaneko, Shun, et al.
Publicado: (2022)

Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease
por: Tamaki, Nobuharu, et al.
Publicado: (2019)

Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not α-Fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor
por: Osawa, Leona, et al.
Publicado: (2020)

Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy
por: Hayakawa, Yuka, et al.
Publicado: (2022)

Simple algorithm to narrow down the candidates to receive echocardiography in patients with chronic liver disease for suspected pulmonary hypertension
por: Yamashita, Koji, et al.
Publicado: (2022)

Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment
por: Kaneko, Shun, et al.
Publicado: (2022)

Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma
por: Takada, Hitomi, et al.
Publicado: (2018)

Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma
por: Matsumoto, Hiroaki, et al.
Publicado: (2022)

Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test
por: Ishido, Shun, et al.
Publicado: (2023)

Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy
por: Itakura, Jun, et al.
Publicado: (2015)

Irregular vascular pattern by contrast‐enhanced ultrasonography and high serum Lens culinaris agglutinin‐reactive fraction of alpha‐fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early‐stage hepatocellular carcinoma
por: Takada, Hitomi, et al.
Publicado: (2016)

Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio
por: Komiyama, Yasuyuki, et al.
Publicado: (2017)

Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B
por: Ishido, Shun, et al.
Publicado: (2023)

Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures
por: Takada, Hitomi, et al.
Publicado: (2019)

Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens
por: Tamaki, Nobuharu, et al.
Publicado: (2015)

Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease
por: Ishido, Shun, et al.
Publicado: (2023)

Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma
por: Tsuchiya, Kaoru, et al.
Publicado: (2014)

Erythema multiforme induced by regorafenib
por: Matsunaga, Mototsugu, et al.
Publicado: (2017)

Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma
por: Ishido, Shun, et al.
Publicado: (2023)

Interaction Between Sex and Organic Anion‐Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib‐N‐Oxide and Regorafenib‐Glucuronide in Mice
por: Fu, Qiang, et al.
Publicado: (2019)

Use of the Serum Wisteria floribunda Agglutinin-Positive Mac2 Binding Protein as a Marker of Gastroesophageal Varices and Liver-Related Events in Chronic Hepatitis C Patients
por: Hayashi, Tsuguru, et al.
Publicado: (2020)

Pretreatment Gastric Lavage Reduces Postoperative Bleeding after Endoscopic Submucosal Dissection for Gastric Neoplasms
por: Nakanishi, Hiroyuki, et al.
Publicado: (2016)

Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma
por: Hong, Young Mi, et al.
Publicado: (2021)

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
por: Kissel, Maria, et al.
Publicado: (2017)

Incidence and risk of regorafenib-induced hepatotoxicity
por: Zhao, Bin, et al.
Publicado: (2017)

Experience with regorafenib in the treatment of hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

Characterization of Glioblastoma Cells Response to Regorafenib
por: Mongiardi, Maria Patrizia, et al.
Publicado: (2022)

Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma
por: Yasui, Yutaka, et al.
Publicado: (2016)

Correction: Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma
por: Yasui, Yutaka, et al.
Publicado: (2016)

Successful Treatment of Hepatocellular Carcinoma with Regorafenib after Sorafenib-induced Hypersensitivity
por: Yoshioka, Naoki, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fli6o8br6oe3okvf6kdbk4omko